Telaprevir

Telaprevir is a peptidomimetic inhibitor of the hepatitis C virus NS3/4A serine protease, developed by Vertex Pharmaceuticals in collaboration with Johnson & Johnson. Approved by the FDA in May 2011 (the same month as boceprevir), telaprevir represented one of the two first-generation direct-acting antivirals (DAAs) that fundamentally changed HCV treatment by directly targeting viral replication machinery rather than relying solely on the host immune response stimulated by interferon.

Telaprevir forms a covalent but reversible complex with the NS3/4A protease active site, inhibiting the enzyme's ability to cleave the HCV polyprotein. This peptidomimetic design was based on detailed structural studies of the NS3/4A protease active site, representing a triumph of structure-based drug design. Telaprevir was approved for use with peginterferon alfa and ribavirin for chronic HCV genotype 1 infection.

The ADVANCE and ILLUMINATE trials demonstrated impressive improvements in SVR rates when telaprevir was added to standard peginterferon/ribavirin therapy. In treatment-naive patients, SVR rates reached 75% with telaprevir-based triple therapy versus 44% with peginterferon/ribavirin alone. The REALIZE trial showed similar benefits in treatment-experienced patients, including those who had null responses to prior interferon-based therapy.

However, telaprevir had significant tolerability issues. A severe and sometimes life-threatening rash (including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms [DRESS]) affected a substantial proportion of patients. Combined with a high pill burden, frequent dosing, and the continued requirement for interferon and ribavirin, telaprevir's clinical use was eclipsed rapidly by second-generation DAAs. Vertex discontinued telaprevir in 2014.